Product Description
BRK (Breast tumor kinase), also known as PTK6 (Protein Tyrosine Kinase 6), is a member of the non-receptor tyrosine kinase family that plays a pivotal role in epithelial cell differentiation, proliferation, migration, and survival. BRK is activated through autophosphorylation and interacts with various signaling molecules, including downstream effectors such as AKT, STAT3, and EGFR signaling pathways. Beyond its physiological functions in normal epithelial tissues, dysregulation of BRK—including overexpression and aberrant activation—is frequently observed in multiple human cancers, such as breast, prostate, ovarian, and colon cancer, contributing to tumor progression, metastasis, and therapeutic resistance. These features have established BRK as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s BRK Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying BRK kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: BRK catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the BRK kinase.
Data